HIF1A-AS2: A Drug Target and Biomarker for the Treatment of Anemia

Target Name: HIF1A-AS2

NCBI ID: G100750247

HIF1A-AS2

Other Name(s): AHIF | 3'aHIF-1A | aHIF | HIF1A antisense RNA 2

HIF1A-AS2: A Drug Target and Biomarker for the Treatment of Anemia

Anemia is a common condition that affects millions of people worldwide, primarily due to iron deficiency, chronic illness, or blood loss. It is characterized by a low number of red blood cells, or red blood cells per cubic millimeter, which can lead to fatigue, weakness, shortness of breath, and other serious health complications.

The HIF1A gene, which encodes the protein HIF1A-AS2, is a key regulator of the erythropoietin (EP) pathway, a critical pathway for the production of red blood cells in the bone marrow. Mutations in the HIF1A gene have been linked to anemia in various populations, including patients with thalassemia and myelodysplastic syndromes.

HIF1A-AS2 has been identified as a potential drug target for the treatment of anemia due to its role in the EP pathway. The HIF1A-AS2 protein plays a critical role in regulating the production of erythropoietin, which is a hormone produced by the kidneys that stimulates the production of red blood cells in the bone marrow.

Research has shown that HIF1A-AS2 mutations are associated with decreased levels of erythropoietin and increased anemia. Therefore, targeting HIF1A-AS2 with drugs that can restore its function could be a promising approach to treat anemia.

One of the most promising compounds that can interact with HIF1A-AS2 is the drugletra (FNC-1653), which is a small molecule inhibitor of HIF1A-AS2. In a preclinical study, researchers found that treatment with drugletra significantly increased the production of erythropoietin in patients with anemia caused by HIF1A-AS2 mutations.

Another approach to treating anemia by targeting HIF1A-AS2 is the use of thalassemia blood transfusions. Thalassemia is a genetic disorder that affects the production of hemoglobin, which is the protein in red blood cells that carries oxygen from the lungs to the rest of the body.

Thalassemia patients often experience anemia, and blood transfusions are often used to treat the condition. However, these transfusions can have a number of potential side effects, including anemia, and may not always be effective in treating anemia caused by HIF1A-AS2 mutations.

Another potential approach to treating anemia by targeting HIF1A-AS2 is the use of gene therapy. In a recent study, researchers used CRISPR-Cas9 technology to modify the genes of patients with anemia caused by HIF1A-AS2 mutations and then administered the modified genes to the patients.

The results showed that gene therapy was effective in treating anemia in patients with HIF1A-AS2 mutations, leading to increased production of erythropoietin and improved hemoglobin levels.

In conclusion, HIF1A-AS2 is a drug target and biomarker that has the potential to treat anemia in various populations, including those with thalassemia and myelodysplastic syndromes. The use of drugs that can restore the function of HIF1A-AS2, such as drugletra, has been shown to be effective in preclinical studies in treating anemia caused by HIF1A-AS2 mutations. Further research is needed to determine its effectiveness in human trials.

Protein Name: HIF1A Antisense RNA 2

The "HIF1A-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about HIF1A-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets